Androgen deprivation‑induced OPHN1 amplification promotes castration‑resistant prostate cancer
{{output}}
Androgen deprivation therapy (ADT) is used to treat prostate cancer (PCa). However, ADT may increase the expression of androgen receptor (AR) through the amplification of chromosome X. The gene oligophrenin 1 (OPHN1) is located in the same region as the AR gen... ...
